-

Segal Trials Kicks Off CISCRP’s 8th Annual Medical Heroes Appreci-A-Thon

MIAMI--(BUSINESS WIRE)--Over 90 Segal Trials employees have joined CISCRP’s 8th Annual Medical Heroes Appreci-A-Thon, a two-week event combining physical activity and fundraising to recognize the clinical research participants and professionals who make medical progress possible.

As clinical research sites have grown and evolved into larger, more sophisticated organizations, I think it can be easy to lose sight of the very human purpose behind what we do,” said Bonnie Segal, President of Segal Trials.

Share

Running September 1 through September 15, the Appreci-A-Thon raises funds to support CISCRP’s work educating and empowering patients and the public about clinical research. Just two days into the challenge, Segal Trials has already raised $2,500 in support of CISCRP’s mission. Segal Trials Team Fight Club also kicked off the event with more than 81,000 Footprint Points logged.

For Segal Trials, the event is also an opportunity to reflect on the people and purpose behind the work.

“As clinical research sites have grown and evolved into larger, more sophisticated organizations, I think it can be easy to lose sight of the very human purpose behind what we do,” said Bonnie Segal, President of Segal Trials. “For all the science, innovation and investment that go into developing new treatments, progress still depends on people. It depends on people willing to participate in research and people who have chosen to dedicate their careers to advancing medicine.”

Segal Trials has seen that impact in very personal ways. Participants have shared stories about returning to work, feeling better and the difference that made in their families and relationships. Research has connected people with physicians, diagnostic testing, and potential care options they might not otherwise have had. For others, medical care and diagnostic testing during a trial uncovered serious health issues they didn’t know they had.

But being a Medical Hero is also about what participants contribute to others. Someone who volunteers for a study today may contribute to a treatment that changes another person’s life years from now, without ever knowing who ultimately benefited. Research professionals make their own commitment, devoting their careers to making that progress possible.

Segal Trials and CISCRP have worked together for years to increase awareness and understanding of clinical research, particularly in diverse communities such as South Florida. Their work has included AWARE for All, the Latina Expo, and a clinical trial awareness event at Marlins Park, now loanDepot park.

Our annual Appreci-a-thon event is an opportunity to get active, but most importantly, it’s a chance to show our appreciation for everyone involved in clinical research. These everyday heroes make the development of new medical treatments and advancements possible.” - Ayse Gunduz.

Individuals can register through CISCRP and participate in the Medical Heroes Appreci-A-Thon through Friday, September 4.

REGISTRATION LINK: https://ciscrp.charityfootprints.com/appreciathon

The Appreci-A-Thon is a chance to recognize something that can be easy to overlook in the day-to-day work of clinical research. Every study depends on people willing to give their time to participate and people committed to making research possible. Their roles may be different, but each contributes to something larger by advancing medicine and helping create better treatments and better lives.

Contacts

More News From Segal Trials

Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study

MIAMI LAKES, Fla.--(BUSINESS WIRE)--Segal Trials today announced its participation in the Phase 2 ZEPHYR clinical trial evaluating MapLight Therapeutics’ investigational muscarinic receptor-targeted therapy, ML-007C-MA, for the treatment of adults experiencing an acute exacerbation of schizophrenia.MapLight Therapeutics recently announced topline results from the multicenter Phase 2 study. Segal Trials is proud to have contributed to this important clinical development program and congratulates...

As Federal Fast-Tracking Accelerates Psychedelic Therapies, Segal Trials Is Positioned to Support the Next Phase of Clinical Development

MIAMI--(BUSINESS WIRE)--The recent federal action directing the FDA to accelerate the review of psychedelic therapies marks a major shift in the development of next-generation mental health treatments. With regulatory timelines compressing and new federal support behind this category, compounds such as psilocybin and ibogaine are moving closer to broader clinical use. For a field that remained largely dormant for decades, this moment represents a clear turning point. “This is an inflection poin...

Segal Trials Participates in Research Leading to FDA Approval of Tonmya™, the First New Fibromyalgia Treatment in More Than 16 Years

MIAMI LAKES, Fla.--(BUSINESS WIRE)--Segal Trials announced its participation as a clinical research site in the pivotal studies that supported the U.S. Food and Drug Administration’s (FDA) approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults. This milestone, announced by Tonix Pharmaceuticals, marks the first new FDA-approved therapy for fibromyalgia in more than 16 years. Dr. Olga Lapeyra, Principal Investigator at Segal Trials, provided lead...
Back to Newsroom